1063 related articles for article (PubMed ID: 19749757)
1. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Tanaka Y; Nishida N; Sugiyama M; Kurosaki M; Matsuura K; Sakamoto N; Nakagawa M; Korenaga M; Hino K; Hige S; Ito Y; Mita E; Tanaka E; Mochida S; Murawaki Y; Honda M; Sakai A; Hiasa Y; Nishiguchi S; Koike A; Sakaida I; Imamura M; Ito K; Yano K; Masaki N; Sugauchi F; Izumi N; Tokunaga K; Mizokami M
Nat Genet; 2009 Oct; 41(10):1105-9. PubMed ID: 19749757
[TBL] [Abstract][Full Text] [Related]
2. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
Guo X; Zhao Z; Xie J; Cai Q; Zhang X; Peng L; Gao Z
Virol J; 2012 Jun; 9():123. PubMed ID: 22713131
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
6. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S
AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173
[TBL] [Abstract][Full Text] [Related]
7. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Suppiah V; Moldovan M; Ahlenstiel G; Berg T; Weltman M; Abate ML; Bassendine M; Spengler U; Dore GJ; Powell E; Riordan S; Sheridan D; Smedile A; Fragomeli V; Müller T; Bahlo M; Stewart GJ; Booth DR; George J
Nat Genet; 2009 Oct; 41(10):1100-4. PubMed ID: 19749758
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
10. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
[TBL] [Abstract][Full Text] [Related]
12. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
[TBL] [Abstract][Full Text] [Related]
13. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
14. Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.
Akkız H; Akgöllü E; Bekar A; Yıldırım S; Sandıkçı M; Ülger Y; Yalınbaş Kaya B; Kuran S; Üsküdar O
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):711-7. PubMed ID: 25857516
[TBL] [Abstract][Full Text] [Related]
15. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
16. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
Chen JY; Lin CY; Wang CM; Lin YT; Kuo SN; Shiu CF; Chang SW; Wu J; Sheen IS
Genes Immun; 2011 Jun; 12(4):300-9. PubMed ID: 21346780
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
18. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
[TBL] [Abstract][Full Text] [Related]
19. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
20. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
